Depression is the most common mood disorder; it is estimated that as many as one of five Americans will meet the criteria for clinical depression at some point in their lives. Fortunately, many of these patients will recover once life circumstances change, and many can be effectively treated with counseling, programs like mindfulness and CBT, and first line anti-depressants. However, one in three patients with clinical depression do not respond to these first line therapies. Psychiatrists can spend months or even years in trial-and- error experimentation to find an effective combination of medication and other therapies, leaving patients and their families needlessly suffering, and health insurers covering the expensive extra costs associated with treatment-resistant depression.
Altimate is working with leading therapeutic providers and academic institutions to improve outcomes for treatment resistant mood disorders.